Intensity Share Price
NASDAQ: INTS | Micro Cap | HealthcareIntensity Stock Performance
Intensity Share Price Chart
Intensity Quarterly Profit & Loss
All figures in USD
Intensity Annual Profit & Loss
All figures in USD
Intensity Balance Sheet
All figures in USD Million
Intensity Cash Flow
All figures in USD Million
Corporate Actions
About Intensity
Intensity Therapeutics Inc is a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction to anti-cancer immune activation. Its new approach involves the direct injection into tumors of a product created from DfuseRxSM discovery platform. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its product candidate, INT230-6 comprised of three components: cisplatin, a anti-cancer cytotoxic agent, vinblastine sulfate, also a anti-cancer cytotoxic agent, and an amphiphilic molecule which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection.
Intensity Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Nov 2026 | $3.46 | $2.60 | -20.97% |
Oct 2026 | $3.30 | $3.29 | -14.55% |
Sep 2026 | $4.11 | $3.85 | -18.26% |
Aug 2026 | $4.25 | $4.71 | +12.68% |
Jul 2026 | $4.16 | $4.18 | +0.72% |
Jun 2026 | $4.37 | $4.15 | -6.74% |
May 2026 | $5.18 | $4.45 | -14.42% |
Apr 2026 | $5.80 | $5.20 | -12.16% |
Mar 2026 | $7.56 | $5.92 | -25.81% |
Feb 2026 | $0.36 | $7.98 | +2,062.60% |
Jan 2026 | $0.41 | $0.37 | -9.11% |
Dec 2025 | $0.38 | $0.41 | +2.01% |